Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON (Reuters) - Sanofi SA and Regeneron Pharmaceuticals Inc filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.